

Financial Tearsheet

Company Overview

Neuropathix, Inc. is a biopharmaceutical medchem company focused on the research and development of a pipeline of patented socially responsible pain management therapeutics to treat patients with significant unmet medical needs. The Company's family of proprietary molecules focuses on treating oxidative stress-related diseases, chronic pain management and neurodegenerative disorders. The therapeutic targets include chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports. Neuropathix conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

Recent Financial News

Date	Headline
May 06, 2021	Neuropathix, Inc. Announces Publication of Validated Preclinical Studies on KLS-13019 in the British Journal of Pharmacology
Jan 25, 2021	Neuropathix, Inc. CEO Recaps 2020 Advances and Potential Ahead
Jan 19, 2021	Neuropathix, Inc. Announces Publication of Its Global PCT Patent for NPTX-204, a Novel Hops-Inspired Neuroprotectant
Jan 12, 2021	Neuropathix, Inc. Appoints World-Renowned Pain Management Clinician Dr. Daniel Richman to the Company's Scientific Advisory Board
Dec 21, 2020	Neuropathix, Inc. Acquires Neuroprotective and Anticonvulsant Intellectual Property Estate

IR Contacts

Investor Relations

Investor Relations Firm
CORE IR
377 Oak Street
Garden City, NY 11530
(516) 222-2285
www.coreir.com
Contact: John Marco
Johnm@coreir.com

Transfer Agent

Securities Transfer Corp.
2901 Dallas Parkway, Suite 380, Plano, TX 75093
(469) 633-0101
www.stctransfer.com

Auditors

DBB McKennon
12790 El Camino Real #130
San Diego, CA 92130
(858) 217-4035
www.dbbmckennon.com
















Corporate Counsel

Procopio, Cory, Hargreaves & Savitch LLP.
525 B Street, Suite 2200
San Diego, CA 92101
(619) 238-1900
www.procopio.com

Stock Performance

Today's Open	0.1600
Volume	37,750
Day Range	0.1400 - 0.1600
52 Week Range	0.1010 - 1.5000
Bid/Ask	0.0000 / 0.0000
Bid/Ask Size	0 X 0
Previous Close	0.1600
Market Cap	12.22 million
Shares Outstanding	87.29 million
Dividend/Yield	0.0000 / 0.0000%
EPS (TTM)	-0.060800
P/E Ratio (TTM)	N/A

Recent XBRL Filings

Filing Date ▾	Form Type	Description	View
Mar 30, 2021	10-K	Annual report	  
Nov 12, 2020	10-Q	Quarterly report	  
Aug 12, 2020	10-Q	Quarterly report	  
May 14, 2020	10-Q	Quarterly report	  
Mar 30, 2020	10-K	Annual report	  

Management Team

Dean Petkanas, Chairman & CEO

William A. Kinney, PHD, Chief Scientific Officer

Thoma Kikis, Chief Communications Officer, Board Director

Mark Corrao, Chief Financial Officer

Board of Directors

Dean Petkanas, Chairman & CEO

Thoma Kikis, Founder / Chief Communications Officer, Board Director

Robert Malasek, Director

Blake Schroeder, Director

Timothy Scott, PhD, Director